

## CIRM Funded Clinical Trials

### Evaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury

<b>Disease Area:</b>	Spinal Cord Injury
<b>Investigator:</b>	Jane Lebkowski
<b>Institution:</b>	Geron Corporation
<b>CIRM Grant:</b>	CT1-05168 (Closed)
<b>Award Value:</b>	\$6,405,771
<b>Trial Sponsor:</b>	Geron Corporation
<b>Trial Stage:</b>	Phase 1
<b>Trial Status:</b>	Completed
<b>Targeted Enrollment:</b>	5
<b>ClinicalTrials.gov ID:</b>	NCT01217008



Jane Lebkowski

#### Details:

Geron carried out a Phase 1 clinical trial to assess the safety and preliminary activity of escalating doses of human embryonic stem cell (hESC) derived oligodendrocyte progenitor cells for treatment of spinal cord injury. Five patients were treated, all safely and without any serious side effects, before the trial was halted by Geron for financial reasons. The work in this trial later has since been revived by Asterias Biotherapeutics, which is conducting a Phase 1/2 clinical trial that CIRM is funding.

**Source URL:** <http://www.cirm.ca.gov/clinical-trial/evaluation-safety-and-preliminary-efficacy-escalating-doses-grnopc1-subacute-spinal>